Biopta has been providing contract research services to the pharmaceutical industry since 2002. Now part of the REPROCELL group, it is the world leader in the use of fresh functional human tissues to better predict drug activity prior to clinical trials.
We can help you reduce risk in drug development by providing early information based on human fresh tissue.
Data from human fresh tissue gives an accurate indication of human safety and efficacy, many years in advance of your compound reaching the clinical setting.
This invaluable information allows you to make ‘go’ or ‘no-go’ decisions with certainty based on human data rather than with data from an animal model or cell culture which might be entirely irrelevant.
Our expertise in all areas of human tissues research – including sourcing, handling and experimenting on human tissue – allows us to act as your “Human Tissue Research Department”.
“Biopta has provided Proteon with high quality data in human tissue to guide dose selection for human clinical trials. The information has been extremely valuable in demonstrating the potential benefit of PRT-201 in patients needing haemodialysis access or treatment of peripheral arterial disease.”
— Senior Vice President and Chief Medical Officer, Proteon Therapeutics Inc.
With regular and frequent access to both healthy and diseased tissues, Biopta can perform comparison studies in different patient populations.
The data we provide will enable you to streamline your proof-of-concept studies; saving you time and money. You can also test your drugs for efficacy in alternative indications using one or more of our human tissue assays.
Our models are considerably more cost effective than setting up a clinical efficacy study which has no guarantee of success. In most cases, our data can be available within weeks of study initiation.
All too frequently, unwanted or adverse side effects are revealed in the clinic. Most times, these were never predicted in the animal models employed throughout pre-clinical development.
At Biopta we can help you investigate these occurrences using human tissues or can recommend human tissue assays that will help confirm the safety of your compound during discovery or non-clinical development.
This data will allow you to modify or even halt your compounds before any expensive trials are undertaken.
“I am very pleased with our cooperation so far; nice data and very good fit to our internal knowledge of the compounds.”
— Senior Scientist, Top 20 European Pharma
Historically, Biopta was the very first Good Laboratory Practice (GLP) certified facility to specialise in fresh human tissue research.
Our Pharma industry customers regularly publish using data generated in our labs – you can find examples of papers we have helped publish here.
Biopta’s validated models will de-risk your drug development programs by predicting the safety, efficacy, absorption or metabolism of your test articles in phenotypically-relevant human tissues.
Download your free Predictive Drug Discovery Brochure today to find out more about how our human fresh tissue services can help power your translational research.